Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 COX 2 inhibitors, traditional NSAIDs, and the heart.

Literature DB >> 15947376

COX 2 inhibitors, traditional NSAIDs, and the heart.

Peter Jüni, Stephan Reichenbach, Matthias Egger.

Abstract

Entities: Gene

Mesh：

Substances：

Year: 2005 PMID： 15947376 PMCID： PMC558270 DOI： 10.1136/bmj.330.7504.1342

Source DB: PubMed Journal: BMJ ISSN： 0959-8138

× No keyword cloud information.

12 in total

1. Better reporting of harms in randomized trials: an extension of the CONSORT statement.

Authors: John P A Ioannidis; Stephen J W Evans; Peter C Gøtzsche; Robert T O'Neill; Douglas G Altman; Kenneth Schulz; David Moher
Journal: Ann Intern Med Date: 2004-11-16 Impact factor: 25.391

2. Lessons from the withdrawal of rofecoxib.

Authors: Paul A Dieppe; Shah Ebrahim; Richard M Martin; Peter Jüni
Journal: BMJ Date: 2004-10-16

3. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.

Authors: Julia Hippisley-Cox; Carol Coupland
Journal: BMJ Date: 2005-06-11

4. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.

Authors: Scott D Solomon; John J V McMurray; Marc A Pfeffer; Janet Wittes; Robert Fowler; Peter Finn; William F Anderson; Ann Zauber; Ernest Hawk; Monica Bertagnolli
Journal: N Engl J Med Date: 2005-02-15 Impact factor: 91.245

5. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.

Authors: Nancy A Nussmeier; Andrew A Whelton; Mark T Brown; Richard M Langford; Andreas Hoeft; Joel L Parlow; Steven W Boyce; Kenneth M Verburg
Journal: N Engl J Med Date: 2005-02-15 Impact factor: 91.245

6. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

Authors: Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron
Journal: N Engl J Med Date: 2005-02-15 Impact factor: 91.245

7. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors:
Journal: JAMA Date: 2002-12-18 Impact factor: 56.272

8. Calcium channel blockers and myocardial infarction. A hypothesis formulated but not yet tested.

Authors: J E Buring; R J Glynn; C H Hennekens
Journal: JAMA Date: 1995 Aug 23-30 Impact factor: 56.272

9. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.

Authors: Peter Jüni; Linda Nartey; Stephan Reichenbach; Rebekka Sterchi; Paul A Dieppe; Matthias Egger
Journal: Lancet Date: 2004 Dec 4-10 Impact factor: 79.321

10. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study.

Authors: Marie Hudson; Hugues Richard; Louise Pilote
Journal: BMJ Date: 2005-06-11

15 in total

1. Novel anti-inflammatory activity of epoxyazadiradione against macrophage migration inhibitory factor: inhibition of tautomerase and proinflammatory activities of macrophage migration inhibitory factor.

Authors: Athar Alam; Saikat Haldar; Hirekodathakallu V Thulasiram; Rahul Kumar; Manish Goyal; Mohd Shameel Iqbal; Chinmay Pal; Sumanta Dey; Samik Bindu; Souvik Sarkar; Uttam Pal; Nakul C Maiti; Uday Bandyopadhyay
Journal: J Biol Chem Date: 2012-05-29 Impact factor: 5.157

Review 2. Recommendations for the use of pharmacological smoking cessation strategies in pregnant women.

Authors: Tim Coleman
Journal: CNS Drugs Date: 2007 Impact factor: 5.749

3. An untold story?

Authors: Jeanne Lenzer; Shannon Brownlee
Journal: BMJ Date: 2008-02-27

Review 4. COX-2 inhibitors and the heart: are all coxibs the same?

Authors: P Sooriakumaran
Journal: Postgrad Med J Date: 2006-04 Impact factor: 2.401

5. Targeting specificity protein 1 transcription factor and survivin using tolfenamic acid for inhibiting Ewing sarcoma cell growth.

Authors: Sagar Shelake; Umesh T Sankpal; W Paul Bowman; Matthew Wise; Anish Ray; Riyaz Basha
Journal: Invest New Drugs Date: 2016-12-26 Impact factor: 3.850

6. Evaluation of inhibitory activities of plant extracts on production of LPS-stimulated pro-inflammatory mediators in J774 murine macrophages.

Authors: Nandini Verma; Subhash K Tripathi; Debasis Sahu; Hasi R Das; Rakha H Das
Journal: Mol Cell Biochem Date: 2009-10-08 Impact factor: 3.396

10. Investigation of Active Anti-Inflammatory Constituents of Essential Oil from Pinus koraiensis (Sieb. et Zucc.) Wood in LPS-Stimulated RBL-2H3 Cells.

Authors: Jiyoon Yang; Won-Sil Choi; Ki-Joong Kim; Chang-Deuk Eom; Mi-Jin Park
Journal: Biomolecules Date: 2021-05-31